Raily Aesthetic Medicine International Holdings Limited (HK:2135)
:2135
Want to see HK:2135 full AI Analyst Report?
Top Page
Raily Aesthetic Medicine International Holdings Limited
(2135)
Select Model
Select Model
Rating:49Neutral
Price Target:
HK$0.14
▼(-19.41% Downside)
Action:Reiterated
Date:05/08/26
The score is mainly driven by a 2025 financial turnaround (profitability and free cash flow improved), but it is tempered by fragile earnings quality (thin net margin and historically volatile results), weak technical momentum, and a high P/E valuation with no dividend support.
Positive Factors
Operational turnaround in 2025
The company returned to small net profitability in 2025 after multi-year losses, showing the business model can generate positive earnings when margins recover. A sustained turnaround improves access to capital, reduces restructuring risk, and creates a base for scaling operations over the medium term.
Negative Factors
Thin net margins and fragile earnings
A very thin net margin offers little buffer against cost inflation, pricing pressure or demand softness. Given prior multi-year losses, persistent thin profitability raises the risk that small adverse changes could revert the company back to losses, limiting durable earnings power.
Read all positive and negative factors
Positive Factors
Negative Factors
Operational turnaround in 2025
The company returned to small net profitability in 2025 after multi-year losses, showing the business model can generate positive earnings when margins recover. A sustained turnaround improves access to capital, reduces restructuring risk, and creates a base for scaling operations over the medium term.
Read all positive factors
Raily Aesthetic Medicine International Holdings Limited (2135) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$77.43M
Dividend YieldN/A
Average Volume (3M)289.64K
Price to Earnings (P/E)41.1
Beta (1Y)0.74
Revenue Growth-4.86%
EPS GrowthN/A
CountryHK
Employees290
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)<0.01
Shares Outstanding557,077,330
10 Day Avg. Volume121,000
30 Day Avg. Volume289,644
Financial Highlights & Ratios
PEG Ratio-0.41
Price to Book (P/B)0.70
Price to Sales (P/S)0.41
P/FCF Ratio2.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Raily Aesthetic Medicine International Holdings Limited Business Overview & Revenue Model
Company Description
Raily Aesthetic Medicine International Holdings Limited, an investment holding company, provides aesthetic medical services. The company operates through three segments: Aesthetic Medical Services, Consulting Services, and Aesthetic Medical Equipm...
How the Company Makes Money
null...
Raily Aesthetic Medicine International Holdings Limited Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
62
Positive
Cash Flow
53
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 184.51M | 199.34M | 189.38M | 164.52M | 188.37M |
| Gross Profit | 75.70M | 71.41M | 71.49M | 66.78M | 69.69M |
| EBITDA | 26.97M | -34.29M | -6.03M | 3.89M | -6.00M |
| Net Income | 1.82M | -59.21M | -32.46M | -15.91M | -17.69M |
Balance Sheet | |||||
| Total Assets | 237.75M | 249.92M | 273.60M | 302.65M | 344.73M |
| Cash, Cash Equivalents and Short-Term Investments | 57.82M | 28.87M | 39.79M | 78.78M | 121.72M |
| Total Debt | 59.18M | 56.37M | 51.78M | 48.22M | 67.45M |
| Total Liabilities | 139.45M | 154.41M | 141.01M | 136.77M | 162.37M |
| Stockholders Equity | 107.88M | 104.13M | 138.12M | 166.08M | 178.22M |
Cash Flow | |||||
| Free Cash Flow | 32.04M | -38.59M | -10.00M | -21.13M | -18.25M |
| Operating Cash Flow | 34.69M | 6.01M | 8.02M | -2.27M | -2.47M |
| Investing Cash Flow | 1.36M | -12.70M | -26.14M | 558.00K | -82.45M |
| Financing Cash Flow | -7.86M | 19.43M | -10.48M | -25.65M | 11.97M |
Raily Aesthetic Medicine International Holdings Limited Technical Analysis
Negative
0.17
Price Trends
0.14
Negative
0.15
Negative
0.14
Positive
Market Momentum
>-0.01
Positive
41.95
Neutral
23.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2135, the sentiment is Negative. The current price of 0.17 is above the 20-day moving average (MA) of 0.14, above the 50-day MA of 0.14, and above the 200-day MA of 0.14, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 41.95 is Neutral, neither overbought nor oversold. The STOCH value of 23.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2135.
Raily Aesthetic Medicine International Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | HK$4.97B | 17.83 | 33.08% | 1.97% | 16.70% | 38.98% | |
58 Neutral | HK$54.35M | 362.73 | -19.93% | ― | -2.91% | 55.41% | |
55 Neutral | HK$24.54M | -197.60 | 138.68% | ― | -20.81% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$77.43M | 41.14 | 1.67% | ― | -4.86% | ― | |
43 Neutral | HK$73.01M | -2.02 | -27.01% | ― | -5.97% | -1594.12% | |
41 Neutral | HK$16.65M | -2.29 | 26.12% | ― | 14.64% | -81.95% |
* Healthcare Sector Average
HK:2135
Raily Aesthetic Medicine International Holdings Limited
0.14
0.02
17.39%
HK:2373
Beauty Farm Medical & Health Industry, Inc.
20.28
1.29
6.79%
HK:8161
MediNet Group Ltd.
0.59
0.26
78.79%
HK:8307
Medicskin Holdings Ltd.
0.12
-0.05
-28.57%
HK:8357
Republic Healthcare Limited
0.12
0.03
27.78%
HK:8437
RMH Holdings Limited
0.25
0.10
66.67%
Raily Aesthetic Medicine International Holdings Limited Corporate Events
Raily Aesthetic Medicine Retools Rights Issue Proceeds for Wider NMPA Approval Push
May 7, 2026
Raily Aesthetic Medicine International Holdings Limited has updated investors on a change in the planned use of the remaining HK$7.6 million in net proceeds from its recent rights issue. Originally earmarked mainly for registration filing and clin...
Raily Aesthetic Medicine Proposes New Memorandum and Articles to Align With Regulatory Changes
Apr 8, 2026
Raily Aesthetic Medicine International Holdings Limited plans to amend its existing second amended and restated memorandum and articles of association to align with updated Hong Kong Listing Rules and relevant Cayman Islands laws, including provis...
Raily Aesthetic Medicine Swings to Shareholder Profit as 2025 Loss Narrows Sharply
Mar 27, 2026
Raily Aesthetic Medicine International Holdings reported revenue of RMB189.4 million for 2025, a slight decline from RMB199.3 million a year earlier, while gross profit improved to RMB77.7 million as cost of sales and operating expenses fell. Othe...
Raily Aesthetic Medicine Brings Biomedical Expert Onto Board as INED
Mar 27, 2026
Raily Aesthetic Medicine International Holdings has appointed biomedical expert Dr. Lin Hai as an independent non-executive director effective March 27, 2026, alongside his roles as chairman of the remuneration committee and member of the audit, n...
Raily Aesthetic Medicine Outlines Board and Committee Structure
Mar 27, 2026
Raily Aesthetic Medicine International Holdings Limited has disclosed the composition of its board of directors, naming Fu Haishu as chairman, Song Jianliang as chief executive officer, and Wang Ying as an executive director. The board also includ...
Raily Aesthetic Medicine Sets March 2026 Board Meeting to Approve 2025 Results
Mar 16, 2026
Raily Aesthetic Medicine International Holdings Limited has scheduled a board meeting for 27 March 2026 to review and approve the audited annual results for the year ended 31 December 2025. The board will also consider whether to declare, recommen...
Raily Aesthetic Medicine Signals Swing to Shareholder Profit in 2025
Mar 4, 2026
Raily Aesthetic Medicine International Holdings Limited, a Hong Kong-listed aesthetic medicine services group with operations in mainland China, focuses on providing medical beauty treatments and related services in the country’s growing cos...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.